The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Current trials in MPN in the UK and the launch of the myMPNVoice app
Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, provides a comprehensive overview of the current key trials in the United Kingdom in the field of myeloproliferative neoplasms (MPN). In essential thrombocythemia (ET), bomedemstat and calreticulin-directed therapies are being investigated. For patients with polycythemia vera (PV), hepcidin agonists are being trialed for reducing venesection requirements and iron deficiency, and the MITHRIDATE study (NCT04116502) is comparing ruxolitinib to hydroxycarbamide or interferon as frontline therapy for high-risk patients. In myelofibrosis (MF), calreticulin-targeting therapies are also being assessed, and several ongoing trials, including FEDORA (ISRCTN88102629) and PROMise (ISRCTN12451433), are investigating combination therapies. Prof. Harrison also highlights the launch of the myMPNVoice app, which will allow patients to track symptoms and facilitate the collection of a large volume of real-world data. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Celgene, Constellation, Novartis; Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra.
